Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

CT-388

Stage Phase 3

Sponsor Hoffmann-La Roche

Route injection

Class GLP-1/GIP

Mechanism The purpose of this study is to evaluate the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), as a therapy to reduce the risk of major adver

Sources

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07918846

A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 8200. Conditions Overweight; Obesity; Cardiovascular Disease. The purpose of this study is to evaluate the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), as a therapy to reduce the risk of major adverse cardiovascular events (MACE) in adult

ClinicalTrials.gov NCT07918846 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07351045

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 2000. Conditions Obesity or Overweight. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Ty

ClinicalTrials.gov NCT07351045 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07351058

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 1600. Conditions Obesity or Overweight; Type 2 Diabetes Mellitus. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesi

ClinicalTrials.gov NCT07351058 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07670416

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 300. Conditions Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM). The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet an

ClinicalTrials.gov NCT07670416 protocol and results modules

registry, as of 2026-11-03

https://clinicaltrials.gov/study/NCT07589686

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Hoffmann-La Roche. Enrollment 486. Conditions Obesity or Overweight. The main purpose of this study is to evaluate the safety and efficacy of the co-administration of petrelintide and enicepatide compared with placebo, petrelintide monotherapy, and enicepatide monotherapy in participants with obesity or overweight with at least one weight-related

ClinicalTrials.gov NCT07589686 protocol and results modules

registry, as of 2026-10-05Stale

https://clinicaltrials.gov/study/NCT06525935

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 469. Conditions Obesity; Overweight. This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidit

ClinicalTrials.gov NCT06525935 protocol and results modules

registry, as of 2026-10-28Stale

https://clinicaltrials.gov/study/NCT06628362

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE2. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 447. Conditions Overweight or Obese; Type 2 Diabetes Mellitus (T2DM). This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

ClinicalTrials.gov NCT06628362 protocol and results modules

registry, as of 2025-10-20Stale

https://clinicaltrials.gov/study/NCT04838405

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus. Overall status COMPLETED. Phases PHASE1. Lead sponsor Carmot Therapeutics, Inc.. Enrollment 129. Conditions Diabetes. This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.

ClinicalTrials.gov NCT04838405 protocol and results modules

Studies

Enith-MACE

Registry NCT07918846

Phase Phase 3

Status Not yet recruiting

Enrollment 8200

Start 2027-01-06

Primary completion 2031-03-20

Study completion 2031-04-17

Arm 1: Placebo

Population Overweight; Obesity; Cardiovascular Disease

Arm 2: Enicepatide

Comparator placebo

Population Overweight; Obesity; Cardiovascular Disease

Enith1

Registry NCT07351045

Phase Phase 3

Status Recruiting

Enrollment 2000

Start 2026-03-16

Primary completion 2028-07-24

Study completion 2028-08-28

Catalyst Primary completion. 2028-07-24. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1: Placebo

Regimen once weekly

Population Obesity or Overweight

Arm 2: Enicepatide Dosing Regimen 1

Regimen once weekly

Comparator placebo

Population Obesity or Overweight

Arm 3: Enicepatide Dosing Regimen 2

Regimen once weekly

Comparator placebo

Population Obesity or Overweight

Arm 4: Enicepatide Dosing Regimen 3

Regimen once weekly

Comparator placebo

Population Obesity or Overweight

Enith2

Registry NCT07351058

Phase Phase 3

Status Recruiting

Enrollment 1600

Start 2026-03-23

Primary completion 2028-08-07

Study completion 2028-08-07

Catalyst Primary completion. 2028-08-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1: Placebo

Regimen once weekly

Population Obesity or Overweight; Type 2 Diabetes Mellitus

Arm 2: Enicepatide Dosing Regimen 1

Regimen once weekly

Comparator placebo

Population Obesity or Overweight; Type 2 Diabetes Mellitus

Arm 3: Enicepatide Dosing Regimen 2

Regimen once weekly

Comparator placebo

Population Obesity or Overweight; Type 2 Diabetes Mellitus

Arm 4: Enicepatide Dosing Regimen 3

Regimen once weekly

Comparator placebo

Population Obesity or Overweight; Type 2 Diabetes Mellitus

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Registry NCT07670416

Phase Phase 3

Status Recruiting

Enrollment 300

Start 2026-07-03

Primary completion 2028-02-24

Study completion 2028-03-15

Catalyst Primary completion. 2028-02-24. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Enicepatide Dose 1

Regimen once weekly

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM)

Enicepatide Dose 2

Regimen once weekly

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM)

Enicepatide Dose 3

Regimen once weekly

Comparator placebo

Population Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM)

Placebo

Regimen once weekly

Population Obesity; Overweight; Type 2 Diabetes Mellitus (T2DM)

ZYNERGY

Registry NCT07589686

Phase Phase 2

Status Not yet recruiting

Enrollment 486

Start 2026-11-30

Primary completion 2027-11-12

Study completion 2028-01-31

Catalyst Primary completion. 2027-11-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Arm 1: Petrelintide + Enicepatide Dosing Regimen 1

Regimen once weekly

Comparator placebo

Population Obesity or Overweight

Arm 2: Petrelintide + Enicepatide Dosing Regimen 2

Regimen once weekly

Comparator placebo

Population Obesity or Overweight

Arm 3: Petrelintide + Enicepatide Dosing Regimen 3

Regimen once weekly

Comparator placebo

Population Obesity or Overweight

Arm 4: Petrelintide-matching Placebo + Enicepatide

Regimen once weekly

Population Obesity or Overweight

Arm 5: Petrelintide + Enicepatide-matching Placebo

Regimen once weekly

Population Obesity or Overweight

Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo

Regimen once weekly

Population Obesity or Overweight

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Registry NCT06525935

Phase Phase 2

Status Completed

Enrollment 469

Start 2024-08-16

Primary completion 2025-12-08

Study completion 2025-12-08

Catalyst Primary completion. 2025-12-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1: Placebo

Regimen once weekly

Weeks 48

Population Obesity; Overweight

Arm 2: Enicepatide Dose Level 1 (Low)

Regimen once weekly

Weeks 48

Comparator placebo

Population Obesity; Overweight

Arm 3: Enicepatide Dose Level 2

Regimen once weekly

Weeks 48

Comparator placebo

Population Obesity; Overweight

Arm 4: Enicepatide Dose Level 3

Regimen once weekly

Weeks 48

Comparator placebo

Population Obesity; Overweight

Arm 5: Enicepatide Dose Level 4

Regimen once weekly

Weeks 48

Comparator placebo

Population Obesity; Overweight

Arm 6: Enicepatide Dose Level 5 (High)

Regimen once weekly

Weeks 48

Comparator placebo

Population Obesity; Overweight

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Registry NCT06628362

Phase Phase 2

Status Completed

Enrollment 447

Start 2024-11-21

Primary completion 2026-05-29

Study completion 2026-10-02

Catalyst Primary completion. 2026-05-29. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Arm 1: Placebo

Regimen once weekly

Weeks 48

Population Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)

Arm 2: Enicepatide Dose Level 1 (Low)

Regimen once weekly

Weeks 48

Comparator placebo

Population Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)

Arm 3: Enicepatide Dose Level 2

Regimen once weekly

Weeks 48

Comparator placebo

Population Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)

Arm 4: Enicepatide Dose Level 3

Regimen once weekly

Weeks 48

Comparator placebo

Population Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)

Arm 5: Enicepatide Dose Level 4 (High)

Regimen once weekly

Weeks 48

Comparator placebo

Population Overweight or Obese; Type 2 Diabetes Mellitus (T2DM)

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

Registry NCT04838405

Phase Phase 1

Status Completed

Enrollment 129

Start 2021-04-29

Primary completion 2024-06-18

Study completion 2024-08-02

CT-388

Comparator placebo

Population Diabetes

Placebo

Population Diabetes

CT-388 Optional

Comparator placebo

Population Diabetes

CT-388 MD

Comparator placebo

Population Diabetes